<DOC>
	<DOC>NCT00219804</DOC>
	<brief_summary>The primary objective of this study was to establish the absolute reduction of chorea in participants with Huntington's disease(HD) treated with tetrabenazine or placebo</brief_summary>
	<brief_title>Efficacy and Safety of Tetrabenazine in Chorea</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<criteria>18 years of age or older suffer from manifest HD as confirmed by genetic testing Meet chorea and total functional capacity scores on Unified Huntington's Disease Rating Scale Meet criteria on Hamilton Depression Rating Scale, Unified Parkinson's Disease Rating Scale dysphagia and dysarthria scale Independently ambulatory Exclusion Criteria previous treatment with tetrabenazine unstable or serious medical or psychiatric illness concomitant use identified drugs untreated depression lack of caregiver</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>